ArticleCase reports in oncology

Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

Andreas Blesl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.